(8) Recently, studies have reported that higher baseline levels of serum IL-6 are associated with poor clinical outcomes of AB treatment, suggesting that serum cytokines may serve as biomarkers for AB treatment in HCC. Here, IL6 is linked to hepatocellular carcinoma.